# Syncona portfolio company Anaveon to present updated clinical data

- Link: https://www.directorstalkinterviews.com/syncona-portfolio-company-anaveon-to-present-updated-clinical-data/4121129866
- Published: 2023-10-16T07:18:33+01:00
- Author: Amilia Stone

**Syncona Limited **(LON:SYNC), a leading healthcare company focused on creating,
building and scaling a portfolio of global leaders in life science, has noted that
its portfolio company, Anaveon, has announced that it will present updated clinical
data from the ongoing Phase I dose escalation study of ANV419 in patients with solid
tumours in a poster at the European Society of Medical Oncology (ESMO) annual meeting.
ANV419 is a selective interleukin-2 (IL-2) agonist, a type of protein which has 
the potential to therapeutically enhance a patient’s immune system to respond to
tumours. It has been designed to overcome known challenges with approved IL-2 therapies
and enable the delivery of high dose IL-2 to patients in a way which addresses safety,
tolerability and durability issues seen elsewhere in its use.

**Highlights from the poster presentation include:**

·   Overall, ANV419 continues to demonstrate a potentially differentiated safety
profile to approved IL-2 therapies

·      ANV419, at a dose of 243 µg/kg every two weeks, was determined as the recommended
Phase II dose

·    The study determined that one injection of ANV419 at this dose level delivers
more IL-2 exposure than a full cycle of an approved IL-2 therapy (high dose aldesleukin)

·    A durable response was observed in one patient with advanced immunotherapy-
resistant non-small cell lung cancer (NSCLC)

·     Details of the poster are copied below, with further detail available in the
abstract on the ESMO website

> **Martin Murphy, Chair of Syncona Investment Management Limited, said**: “The 
> data which will be presented at ESMO further underlines the strong safety and 
> tolerability profile of ANV419, demonstrating potential differentiation from other
> IL-2 therapies. We are encouraged by the NSCLC patient who has demonstrated a 
> durable response and now await the full efficacy read-out in the ongoing monotherapy
> trial in melanoma at the recommended Phase II dose.”  

**Poster #** **1031P:** ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/
refractory advanced solid tumours 

**Authors:** E. Calvo, M. Joerger, H. Läubli, J. Lopez, G. Alonso Casal, E. Corral,
D. Hess, D. König, V. S. Perez, E. Gasal, S. Jethwa, D. Di Blasi, E. Garralda

**Date and Time:** Monday, October 23, 2023, at 11:00am-12:00pm BST / 12:00pm-1:
00 pm (CEST),

The accompanying poster will be on display on the ESMO 2023 meeting platform as 
well as on Anaveon’s website from October 23, 2023.

Share on:
